Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.
Abbink P, Kirilova M, Boyd M, Mercado N, Li Z, Nityanandam R, Nanayakkara O, Peterson R, Larocca RA, Aid M, Tartaglia L, Mutetwa T, Blass E, Jetton D, Maxfield LF, Borducchi EN, Badamchi-Zadeh A, Handley S, Zhao G, Virgin HW, Havenga MJ, Barouch DH. Abbink P, et al. Among authors: havenga mj. J Virol. 2018 Feb 26;92(6):e01924-17. doi: 10.1128/JVI.01924-17. Print 2018 Mar 15. J Virol. 2018. PMID: 29298888 Free PMC article.
Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.
Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt DM, Abbink P, Kishko MG, Gorgone DA, Lifton MA, Shen L, Carville A, Mansfield KG, Havenga MJ, Barouch DH. Nanda A, et al. Among authors: havenga mj. J Virol. 2005 Nov;79(22):14161-8. doi: 10.1128/JVI.79.22.14161-14168.2005. J Virol. 2005. PMID: 16254351 Free PMC article.
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.
Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH. Abbink P, et al. Among authors: havenga mj. J Virol. 2007 May;81(9):4654-63. doi: 10.1128/JVI.02696-06. Epub 2007 Feb 28. J Virol. 2007. PMID: 17329340 Free PMC article.
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.
Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. Liu J, et al. Among authors: havenga mj. Nature. 2009 Jan 1;457(7225):87-91. doi: 10.1038/nature07469. Epub 2008 Nov 9. Nature. 2009. PMID: 18997770 Free PMC article.
First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1.
Stephenson KE, Keefer MC, Bunce CA, Frances D, Abbink P, Maxfield LF, Neubauer GH, Nkolola J, Peter L, Lane C, Park H, Verlinde C, Lombardo A, Yallop C, Havenga M, Fast P, Treanor J, Barouch DH. Stephenson KE, et al. PLoS One. 2018 Nov 14;13(11):e0205139. doi: 10.1371/journal.pone.0205139. eCollection 2018. PLoS One. 2018. PMID: 30427829 Free PMC article. Clinical Trial.
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH. Roberts DM, et al. Among authors: havenga mj. Nature. 2006 May 11;441(7090):239-43. doi: 10.1038/nature04721. Epub 2006 Apr 16. Nature. 2006. PMID: 16625206
94 results